January 7, 2021 –APT Medical (SHSE: 688617) successfully listed on the Science and Technology Innovation Board (the STAR Board) of the Shanghai Stock Exchange today. The issue price is CNY 74.46 per share, with 1667K shares issued in total. It will raise RMB 1.2B or USD 180M equivalent to fund the research & development and global products launch mainly.

Founded in Jun. 2002, APT Medical provides coronary artery access and electrophysiological medical devices, peripheral intervention, and nerve intervention medical devices. It has been the leading domestic developer in China. According to the Frost & Sullivan report, APT Medical ranked No.1 in 2019 in terms of market share among domestic electrophysiological medical device providers and ranked Top 3 domestic coronary artery medical device providers. And it has been building a global distributors network and launching the products to international markets.

“The IPO will fasten our efforts to launch our products to the international market. We try to provide high-quality products with affordable cost to physicians and patients. We keep investing heavily in R&D to develop products with super performance, great quality, and affordable cost.” said Michael Cheng, the founder and chairman of APT Medical. “We will keep inviting talents to join us and develop and launch great products in cardiovascular area with great design, high quality, relatively lower cost to meet unmet medical requirements globally.”

Published by APT Medical Inc.

For more information, please contact:

Contact: Miss. Ranran Chen
Tel: +86 755 86951506
Fax: +86 755 83480508
Email: crr@aptmed.com